US equities |
SPCX $167.02 ▲+5.07% NVDA $237.04 ▲+1.32% MU $1,063.87 ▼-1.03% TSLA $378.19 ▲+2.05% MSFT $526.46 ▲+1.73% SNDK $1,715.60 ▼-0.26% INTC $116.67 ▼-2.23% META $745.77 ▲+2.43%
FinancialContent

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

27.00 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
News headline image
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Gold Rises Over 1%; Elys Game Technology Shares Spike Higher ↗
U.S. stocks traded mixed toward the end of trading, with the Dow Jones trading slightly higher on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Major Indexes Falter As Rocky Year Wraps Up ↗
Stocks are struggling to build on their morning gains as investors began to waver on the possibility of a 
Via Talk Markets
News headline image
Dow Rises 100 Points; Crude Oil Rises Over 1% ↗
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Tuesday. 
Via Benzinga
News headline image
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67% ↗
HC Wainwright & Co. cut KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) price target from $48 to $16. KalVista Pharmaceuticals shares fell 1.8% to $5.06 in pre-market trading. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >